Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Jones T Nauseef; Neil H Bander; Scott T Tagawa

doi:10.1016/j.euf.2021.02.006

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Eur Urol Focus. 2021 Mar;7(2):254-257. doi: 10.1016/j.euf.2021.02.006. Epub 2021 Feb 27.

Authors

Jones T Nauseef¹, Neil H Bander¹, Scott T Tagawa²

Affiliations

¹ Weill Cornell Medicine, New York, NY, USA.
² Weill Cornell Medicine, New York, NY, USA. Electronic address: [email protected].

PMID: 33648895
DOI: 10.1016/j.euf.2021.02.006

Abstract

Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond ¹⁷⁷Lu-PSMA-617, which is covered elsewhere. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer tumors and on limited other areas in the body. It can be targeted to treat prostate cancer using radioactive particles, drugs, or immune agents.

Keywords: Bispecific antibodies; Monoclonal antibodies; Prostate cancer; Prostate-specific membrane antigen; Radionuclide; Targeted radionuclide therapy.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Humans
Male
Prostate*
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / radiotherapy